Endothelin-1 levels in patients with Paget's disease of bone

Experimental and Clinical Endocrinology and Diabetes

Volumn 113, Issue 10, 2005, Pages 598-601

  Pirzer, R ^a   Tilly, N ^a   Sommer, U ^a   Liegibel, U ^a   Grafe, I ^a   Nawroth, P ^a   Kasperk, Christian ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

Bisphosphonates; Bone densitometry; Bone turn over markers; Endothelin 1; Paget's disease

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; ENDOTHELIN 1; PAMIDRONIC ACID;

ADULT; AGED; ARTICLE; BONE DENSITY; BONE METABOLISM; CELL METABOLISM; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; HUMAN; PAGET BONE DISEASE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL;

AGED; BIOLOGICAL MARKERS; ENDOTHELIN-1; FEMALE; HUMANS; MALE; MIDDLE AGED; OSTEITIS DEFORMANS;

EID: 29144494450     PISSN: 09477349     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2005-872905     Document Type: Article

References (37)

1. Alam AS, Gallagher A, Shankar V, Ghatei MA, Datta HK, Huang CL, Moonga BS, Chambers TJ, Bloom SR, Zaidi M. Endothelin inhibits osteoclastic bone resorption by a direct effect on cell motility: implications for the vascular control of bone resorption. Endocrinology 1992; 130: 3617-3624
2. Alvarez L, Ricos C, Peris P, Guanabens N, Monegal A, Pons F, Ballesta AM. Components of biological variation of biochemical markers of bone turnover in Paget's bone disease. Bone 2000; 26: 571-576
3. Cawley MI. Complications of Paget's disease of bone. Gerontology 1983; 29: 276-287
4. Cherian RA, Haddaway MJ, Davie MW, McCall IW, Cassar-Pullicino VN. Effect of Paget's disease of bone on areal lumbar spine bone mineral density measured by DXA, and density of cortical and trabecular bone measured by quantitative CT. Br J Radiol 2000; 73: 720-726
5. Coessens BC, Miller VM, Wood MB. Endothelin induces vasoconstriction in the bone vasculature in vitro: an effect mediated by a single receptor population. J Orthop Res 1996; 14: 611-617
6. Cook GJ, Blake GM, Marsden PK, Cronin B, Fogelman I. Quantification of skeletal kinetic indices in Paget's disease using dynamic 18F-fluoride positron emission tomography. J Bone Miner Res 2002; 17: 854-859
7. Eckhoff M, Klift M, Kroon H, Cooper C, Hofman A, Pols H, Papapoulos S. Paget's disease of bone in the Netherlands: A population-based radiological and biochemical survey - the Rotterdam Study. J Bone Miner Res 2004; 19: 566-570
8. Fogelman I, Bessent RG, Turner JG, Citrin DL, Boyle IT, Greig WR. The use of whole-body retention of Tc-99 m diphosphonate in the diagnosis of metabolic bone disease. J Nucl Med 1978; 19: 270-275
9. Fournier P, Boissier S, Filleur S, Guglielmi J, Gabon F, Colombel M, Clezardin P. Bisphosphonates inhibit angiogenesis in vitro and testosterone-stimulated vascular regrowth in the ventral prostate in castrated rats. Cancer Res 2002; 62: 6538-6544
10. Frelin C, Guedin D. Why are circulating concentrations of endothelin-1 so low? Cardiovasc Res 1994; 28: 1613-1622
11. Gonzalez DC, Mautalen CA. Short-term therapy with oral olpadronate in active Paget's disease of bone. J Bone Miner Res 1999; 14: 2042-2047
12. Kasperk C, Helmboldt A, Borcsok I, Heuthe S, Cloos O, Niethard F, Ziegler R. Skeletal site-dependent expression of the androgen receptor in human osteoblastic cell populations. Calcif Tissue Int 1997a; 61: 464-473
13. Kasperk CH, Borcsok I, Schairer HU, Schneider U, Nawroth PP, Niethard FU, Ziegler R. Endothelin-1 is a potent regulator of human bone cell metabolism in vitro. Calcif Tissue Int 1997 b; 60: 368-374
14. Kitano Y, Kurihara H, Kurihara Y, Maemura K, Ryo Y, Yazaki Y, Harii K. Gene expression of bone matrix proteins and endothelin receptors in endothelin-1-deficient mice revealed by in situ hybridization. J Bone Miner Res 1998; 13: 237-244
15. Lariviere R, Lebel M. Endothelin-1 in chronic renal failure and hypertension. Can J Physiol Pharmacol 2003; 81: 607-621
16. Laroche M, Delpech B, Bernard J, Constantin A, Mazieres B. Measurement of bone mineral density by dual X-ray absorptiometry in Paget's disease before and after pamidronate treatment. Calcif Tissue Int 1999; 65: 188-191
17. Masukawa H, Miura Y, Sato I, Oiso Y, Suzuki A. Stimulatory effect of endothelin-1 on Na-dependent phosphate transport and its signaling mechanism in osteoblast-like cells. J Cell Biochem 2001; 83: 47-55
18. Mathieu MN, Hamroun D, Launay JM, Chevillard C. Human bone marrow platelet progenitors express and release endothelin-1. J Cardiovasc Pharmacol 1998; 31 (Suppl 1): 509-511
19. Meunier PJ, Coindre JM, Edouard CM, Arlot ME. Bone histomorphometry in Paget's disease. Quantitative and dynamic analysis of pagetic and nonpagetic bone tissue. Arthritis Rheum 1980; 23: 1095 -1103
20. Michel RP, Langleben D, Dupuis J. The endothelin system in pulmonary hypertension. Can J Physiol Pharmacol 2003; 81: 542-554
21. Miyazaki T, Hirose N, Kawamura J, Kageyama Y, Iikuni K, Yanagishita T. A case of generalized Paget's disease of bone complicating high output heart failure. Nippon Naika Gakkai Zasshi 1983; 72: 47-54
22. Owen M. Marrow stromal stem cells. J Cell Sci 1988; 10 (Suppl): 63-76
23. Roodman GD. Paget's disease and osteoclast biology. Bone 1996; 19: 209-212
24. Roux C, Gennari C, Farrerons J, Devogelaer JP, Mulder H, Kruse HP, Picot C, Titeux L, Reginster JY, Dougados M. Comparative prospective, double-blind, multicenter study of the efficacy of tiludronate and etidronate in the treatment of Paget's disease of bone. Arthritis Rheum 1995; 38: 851-858
25. Rubanyi GM, Botelho LH. Endothelins. FASEB J 1991; 5: 2713-2720
26. Schiepers C, Nuyts J, Bormans G, Dequeker J, Bouillon R, Mortelmans L, Verbruggen A, De Roo M. Fluoride kinetics of the axial skeleton measured in vivo with fluorine-18-fluoride PET. J Nucl Med 1997; 38: 1970-1976
27. Schneider JG, Tilly N, Hierl T, Sommer U, Hamann A, Dugi K, Leidig-Bruckner G, Kasperk C. Elevated plasma endothelin-1 levels in diabetes mellitus. Am J Hypertens 2002; 15: 967-972
28. Shioide M, Noda M. Endothelin modulates osteopontin and osteocalcin messenger ribonucleic acid expression in rat osteoblastic osteosarcoma cells. J Cell Biochem 1993; 53: 176-180
29. Stern PH, Tatrai A, Semler DE, Lee SK, Lakatos P, Strieleman PJ, Tarjan G, Sanders JL. Endothelin receptors, second messengers, and actions in bone. J Nutr 1995; 125: 2028-2032
30. Tarquini R, Perfetto F, Tarquini B. Endothelin-1 and Paget's bone disease: is there a link? Calcif Tissue Int 1998; 63: 118-120
31. Thiebaud D, Jaeger P, Gobelet C, Jacquet AF, Burckhardt P. A single infusion of the bisphosphonate AHPrBP (APD) as treatment of Paget's disease of bone. Am J Med 1988; 85: 207-212
32. Tilly N, Schneider JG, Leidig-Bruckner G, Sommer U, Kasperk C. Endothelin-1 levels in patients with disorders of the thyroid gland. Exp Clin Endocrinol Diabetes 2003; 111: 80-84
33. Tsukahara H, Hori C, Hiraoka M, Yamamoto K, Ishii Y, Mayumi M. Endothelin subtype A receptor antagonist induces osteopenia in growing rats. Metabolism 1998; 47: 1403-1407
34. Vane J. Endothelins come home to roost. Nature 1990; 348: 673
35. Yanagisawa M, Kurihara H, Kimura S, Goto K, Masaki T. A novel peptide vasoconstrictor, endothelin, is produced by vascular endothelium and modulates smooth muscle Ca2+ channels. J Hypertens 1988; 6 (Suppl): 188-191
36. Yin JJ, Mohammad KS, Kakonen SM, Harris S, Wu-Wong JR, Wessale JL, Padley RJ, Garrett IR, Chirgwin JM, Guise TA. A causal role for endothelin-1 in the pathogenesis of osteoblastic bone metastases. Proc Natl Acad Sci USA 2003; 100: 10954-10959
37. Ziegler R, Holz G, Rotzler B, Minne H. Paget's disease of bone in West Germany. Prevalence and distribution. Clin Orthop 1985; 194: 199-204